Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02218463 · ClinicalTrials.gov registry record · NA
Treatment of Prepubertal Labial Adhesions
A NA study, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT02218463: Completed NA study, sponsored by Children's Mercy Hospital Kansas City.
NCT02218463 is a NA study that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02218463, a NA study, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
First-line treatment for labial adhesions in prepubertal girls has been topical estrogen. This study aims to evaluate an alternative and less costly option of treatment with potentially less side effects. Primary Hypothesis: There will be a difference in complete resolution of labial adhesions with topical estrogen with lateral traction as compared to an emollient with lateral traction.
Primary Outcome
The first assessment will be 3 weeks after initiation of treatment. The final assessment will be 6 weeks after initiation of treatment.
Interventions
- DRUG Cetaphil
- DRUG Estradiol cream 0.01%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-06 |
| Phase | NA |
What the finished NCT02218463 record still lists
NCT02218463 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Cetaphil is the first listed.
NCT02218463 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02218463 about?
NCT02218463 is a clinical study titled "Treatment of Prepubertal Labial Adhesions". First-line treatment for labial adhesions in prepubertal girls has been topical estrogen. This study aims to evaluate an alternative and less costly option of treatment with potentially less side effects. Primary Hypothesis: There will be a difference in complete resolution of labial adhesions wit...
What is the current status of trial NCT02218463?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2014-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02218463?
The interventions under investigation include: Cetaphil (DRUG), Estradiol cream 0.01% (DRUG).
Who is sponsoring clinical trial NCT02218463?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02218463's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia